01 1Qilu Antibiotics Pharmaceutical Co., Ltd.
01 1CEFIXIME
01 1China
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2022-11-28
Pay. Date : 2022-08-19
DMF Number : 36694
Submission : 2022-07-22
Status : Active
Type : II
20
Qilu Antibiotics Pharmaceutical Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is CEFIXIME, with a corresponding US DMF Number 36694.
Remarkably, this DMF maintains an Active status since its submission on July 22, 2022, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of November 28, 2022, and payment made on August 19, 2022, indicating their dedication to facilitating drug approvals, Categorized as Type II
